Tucked in its Q4 earnings press release, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) reported a setback on the early-stage BCX10013 study. The company noted recent dose-related observations in an ongo...
Tucked in its Q4 earnings press release, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) reported a setback on the early-stage BCX10013 study. The company noted recent dose-related observations in an ongo...